From Alzheimer’s to spinal cord injury, neuroscience research is zeroing in on precision. Whether it’s improving memory in early Alzheimer’s with antibody therapies like lecanemab, exploring how glutamate receptors can help manage Parkinson’s symptoms, or tuning the immune response after spinal cord injury, scientists are shifting from one-size-fits-all approaches to more refined, biologically informed strategies.
These recent studies highlight not only the importance of targeting the right molecules at the right time but also the growing role of biomarkers in guiding care. Together, they reflect a broader move toward smarter, more adaptive therapies—designed not just to treat symptoms, but to intervene in the underlying biology of brain and spinal cord disorders.
1. Lecanemab treatment for Alzheimer’s Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China
A multi-center study in China shows that Lecanemab improves cognitive outcomes in early Alzheimer’s and reduces key plasma biomarkers like p-tau181 and p-tau217. The results highlight its short-term safety and suggest these biomarkers may help monitor and predict treatment response.
2. Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease
This review explores how metabotropic glutamate (mGlu) receptors could be targeted to treat both motor and non-motor symptoms of Parkinson’s disease. Their role in neuroinflammation, excitotoxicity, and synaptic plasticity makes them promising for both symptom control and disease modification.
3. Neuroinflammation: targeting microglia for neuroprotection and repair after spinal cord injury
After spinal cord injury, microglia play both protective and damaging roles depending on timing and context. Emerging therapies aim to fine-tune their response—reducing harmful inflammation while promoting tissue repair and functional recovery.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
